MDL | - |
---|---|
Molecular Weight | 534.68 |
Molecular Formula | C30H46O8 |
SMILES | O[C@@]12[C@@]3([H])[C@@](CC[C@@]1([C@](C4=CC(OC4)=O)([H])CC2)C)([H])[C@@]5([C@](C[C@H](CC5)O[C@H]6[C@H]([C@@H]([C@H]([C@@H](O6)C)O)OC)O)([H])CC3)C |
Neriifolin, a CNS-penetrating cardiac glycoside, is an inhibitor of the Na + , K + -ATPase. Neriifolin can target beclin 1, inhibits the formation of LC3-associated phagosomes and ameliorates experimental autoimmune encephalomyelitis (EAE) development. Neriifolin induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells [1] [2 .
Neriifolin (0.1μg/mL; 48 hours) induces apoptosis in HepG2 cells. Neriifolin (0-8 μg/mL; 72 hours) reduces viability of HepG2 cells. Neriifolin also induces S and G2/M phase arrests of the cell cycle and stimulates apoptosis of HepG2 cells. Stimulation of HepG2 cells with Neriifolin induced activation of caspase-3, -8, and -9, and up-regulated expression of Fas and FasL proteins [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 100 mg/mL ( 187.03 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 1.8703 mL | 9.3514 mL | 18.7028 mL |
5 mM | 0.3741 mL | 1.8703 mL | 3.7406 mL |
10 mM | 0.1870 mL | 0.9351 mL | 1.8703 mL |
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution